Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

University of Chinese Academy Sciences

Status and phase: Enrolling; Phase 2

Conditions: Nasopharyngeal Carcinoma

Treatments: Drug: Endostar and Envafolimab

Study type: Interventional

Funder types: Other

Identifiers

NCT06055816

GEE study

Details and patient eligibility

About

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Enrollment: 40 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥65 years with newly pathologically confirmed NPC
• Karnofsky performance status ≥60
• Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)
• Adequate organ function

Exclusion criteria

• Cancer history
• Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
• Life-expectance within 6 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Gemcitabine Combined With Endostar and Envafolimab

Experimental group

Description:

Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.

Treatment:

Drug: Endostar and Envafolimab